Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Shares Outstanding (2019 - 2025)

Eton Pharmaceuticals' Shares Outstanding history spans 7 years, with the latest figure at $26.8 million for Q3 2025.

  • For Q3 2025, Shares Outstanding rose 3.8% year-over-year to $26.8 million; the TTM value through Sep 2025 reached $26.8 million, up 3.8%, while the annual FY2024 figure was $26.7 million, 3.97% up from the prior year.
  • Shares Outstanding for Q3 2025 was $26.8 million at Eton Pharmaceuticals, roughly flat from $26.8 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $25.7 billion in Q1 2024 and bottomed at $24.5 million in Q1 2021.
  • The 5-year median for Shares Outstanding is $25.6 million (2023), against an average of $1.4 billion.
  • The largest annual shift saw Shares Outstanding surged 100630.01% in 2024 before it tumbled 99.9% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $24.6 million in 2021, then increased by 2.95% to $25.4 million in 2022, then rose by 1.32% to $25.7 million in 2023, then rose by 3.97% to $26.7 million in 2024, then grew by 0.41% to $26.8 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's Shares Outstanding are $26.8 million (Q3 2025), $26.8 million (Q2 2025), and $26.8 million (Q1 2025).